Trials / Completed
CompletedNCT04500821
Evaluation of the LipiFlow System With a New Activator
Evaluation of the LipiFlow System With a New Activator (Model LFD-2100)
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- Johnson & Johnson Surgical Vision, Inc. · Industry
- Sex
- All
- Age
- 22 Years
- Healthy volunteers
- Not accepted
Summary
Minimum 50 eyes and up to 100 eyes will be treated in this prospective, open-label clinical study. The investigator or designee will perform LipiFlow treatment with the Activators LFD-2100 on both eyes of a subject. The data from the treatment reports generated by the LipiFlow console and from the questionnaire will be used to assess the clinical utilization of the Activator LFD-2100. This study will be conducted in up to four sites in the USA.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Activator LFD-2100 | LipiFlow treatment with the Activators LFD-2100 will be performed on both eyes with MGD |
Timeline
- Start date
- 2020-10-02
- Primary completion
- 2020-10-30
- Completion
- 2020-10-30
- First posted
- 2020-08-05
- Last updated
- 2022-01-24
- Results posted
- 2022-01-24
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT04500821. Inclusion in this directory is not an endorsement.